Dexamethasone-Mediated Activation of Fibronectin Matrix Assembly Reduces Dispersal of Primary Human Glioblastoma Cells - Fig 2

<p><b>(A)</b> Dex treatment activates FNMA in GBM cells. Immunofluorescence was used to compare FNMA in untreated and Dex treated GBM cells. Dex was added to a final concentration of 1x10⁻⁷M. Cells were treated for 24 hours prior to fixation. Dex treatment significantly increased FNMA in all lines. <b>(B)</b> Dex-mediated upregulation of FNMA was confirmed by immunoblot analysis. Lysates of untreated and Dex-treated cells were prepared by DOC differential solubilization and soluble (sFN) and insoluble (InsFN) fractions of FN were separated by SDS-PAGE. Note the increase in both soluble and insoluble fibronectins in response to Dex treatment. <b>(C)</b> 3D spheroids of GBM-3 were generated in the presence or absence of Dex and 50 μg/ml Rhodamine-conjugated FN. Dex treatment resulted in a marked re-organization of FN from punctate to fibrous (left panel). FNMA by spheroids was also assessed by DOC/SDS-PAGE and immunoblot analysis. Note the presence of insoluble fibronectin in response to Dex treatment (right panel).